YERVOY (ipilimumab) is a recombinant, fully human monoclonal antibody that targets CTLA-4, a negative regulator of T-cell activation. By binding to CTLA-4, YERVOY enhances the immune system’s antitumor response through T-cell activation and proliferation. It is administered via intravenous infusion and has demonstrated clinical efficacy in multiple solid tumor malignancies when used alone or synergistically in combination with immune checkpoint inhibitors such as nivolumab.
Initially approved in 2011, YERVOY has since expanded its indications across various cancer types, including melanoma, RCC, CRC, HCC, and NSCLC. Its utility spans both first-line and adjuvant settings, with a particular focus on tumors characterized by high mutational burden or immune susceptibility. The combination with nivolumab enhances dual checkpoint blockade, promoting durable anti-tumor immunity. Dosing, safety, and administration specifics are regulated and require close adherence to clinical guidelines. Further pharmacologic details and long-term safety data are not specified in the specification.
